Skip to main content
    R

    Rockwell Medical Inc (RMTI)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $6.76
    -0.27 (-3.84%)

    Market Cap: $27.92M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Rockwell Medical Inc (RMTI) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Rockwell Medical (RMTI) trades at 0.4x sales and 0.8x book value. Its P/S of 0.4x is below its 5-year median of 0.5x. Its forward P/E is 19.5x.

    Current Multiples

    Its free cash flow yield is 3.1%.

    MultipleValue
    P/E (trailing)N/A
    Forward P/E19.5x
    Price to sales0.4x
    Price to book0.8x
    Price to FCF32.4x
    EV/FCF30.5x
    PEGN/A
    FCF yield3.1%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 50.0% below 0.8x and its P/B is 80.5% below 4.1x.

    MultipleCurrent5-year median10-year median
    P/S0.4x0.5x0.8x
    P/B0.8x1.4x4.1x
    Medians of month-end values through Oct 2026: 54 to 60 months (5-year) and 103 to 114 months (10-year).

    Valuation History

    Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 0.2x in 2022 to 8.2x in 2016.

    Year endPriceP/SP/B
    2025$8.340.4x0.9x
    2024$20.400.6x2.1x
    2023$18.900.7x2.5x
    2022$10.150.2x0.8x
    2021$45.100.8xN/A
    2020$111.111.1x2.1x
    2019$268.43N/A7.7x
    2018$248.626.0x100.6x
    2017$640.266.7x8.9x
    2016$720.578.2x6.3x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About RMTI

    What is RMTI's forward P/E ratio?

    Rockwell Medical has a forward P/E ratio of 19.5x.

    What is RMTI's price to sales ratio?

    Rockwell Medical has a price to sales ratio of 0.4x.